There should be a study for prevention of Airflow Obstruction Progression. Rationale: All diseases have a prodrome followed by an early face of disease progression. Complex medical chronic diseases can only be slowed through the addition of several interventions all of which contribute to a final improvement of prognosis (witness CV diseases). Definition of “Early Disease”: Would be aimed at patients with airflow obstruction ...more »
Specific biomarkers to monitor COPD disease activity are needed.
What is the comparative effectiveness of using symptoms vs. spirometry in increasing patient and provider adherence to COPD treatment guidelines and patient-reported outcomes (symptom frequency, activities of daily living, quality of life, sleep quality, exacerbations)?
There are two broad issues that any future clinical trials in COPD need to seriously consider, that of the challenges of timely and efficient subject recruitment and the need to increase the participation of low to middle income countries that experience a disproportionate burden of COPD in evidence generation. My specific suggestions are as follows: 1) Address the optimal medical management of multiple physical and psychological ...more »
What are there specific alterations of mast cell populations in COPD, and what role do they have in determining specific histopathological phenotypes of the disease?
How do we generalize our educational efforts such that multiple co-morbidities and their self-care can be addressed?
What is the comparative effectiveness of a Non-invasive vs. Invasive Positive Pressure
Ventilation Protocol for managing acute respiratory failure due to acute exacerbations of COPD
What is the nature of, and what are the best treatments for, heart failure in COPD?
Does use of periodic and automatic multidisciplinary team consultation improve care and health outcomes of patients with COPD?
COPD hospitalizations a. Define the pathobiological changes that lead to severe exacerbations that cause hospitalizations b. Define novel clinical and biological phenotypic characterizations of hospitalized patients who fail treatment that results in death or early readmission c. Explore new or understudied therapies for treatment of acute COPD hospitalizations: antioxidant, non-steroidal anti-inflammatory (STATIN or ...more »
Can normoxemic patients with COPD benefit from oxygen supplementation?
Azithromycin is very effective at reducing exacerbations in COPD, but we do not understand the biological mechanism, i.e. anitbiotic effect versus antiinflammatory effect. Because we do not understand how it works (and because of the potential for side effects), azithromycin is not yet widely used. Clinical studies designed to answer this question would help us refine our therapeutic approach and may allow us to minimze ...more »